Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits

Cell Metabolism

Volumn 13, Issue 4, 2011, Pages 428-439

  Hult, Sofia ^a   Soylu, Rana ^a   Björklund, Tomas ^a   Belgardt, Bengt F ^b   Mauer, Jan ^b   Brüning, Jens C ^b   Kirik, Deniz ^a   Petersén, Åsa ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HUNTINGTIN; INSULIN; LEPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GENE MUTATION; GLUCOSE METABOLISM; HYPERPHAGIA; HYPOTHALAMUS; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOVIRIDAE; ANIMALS; FEMALE; GENE EXPRESSION REGULATION; HUNTINGTON DISEASE; HYPOTHALAMUS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; MALE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NUCLEAR PROTEINS; PHENOTYPE;

BACTERIA (MICROORGANISMS); MUS;

EID: 79953756679     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2011.02.013     Document Type: Article

References (50)

1. Aziz, A., Fronczek, R., Maat-Schieman, M., Unmehopa, U., Roelandse, F., Overeem, S., van Duinen, S., Lammers, G.J., Swaab, D., and Roos, R. (2008). Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 18, 474-483.
2. Belgardt, B.F., Okamura, T., and Bruning, J.C. (2009). Hormone and glucose signalling in POMC and AgRP neurons. J. Physiol. 587, 5305-5314.
3. Belgardt, B.F., Mauer, J., Wunderlich, F.T., Ernst, M.B., Pal, M., Spohn, G., Bronneke, H.S., Brodesser, S., Hampel, B., Schauss, A.C., et al. (2010). Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. Proc. Natl. Acad. Sci. USA 107, 6028-6033.
4. Bjorkqvist, M., Petersen, A., Bacos, K., Isaacs, J., Norlen, P., Gil, J., Popovic, N., Sundler, F., Bates, G.P., Tabrizi, S.J., et al. (2006). Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 15, 1713-1721.
5. Boudreau, R.L., McBride, J.L., Martins, I., Shen, S., Xing, Y., Carter, B.J., and Davidson, B.L. (2009). Nonallele-specific silencing of mutant and wt huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063.
6. Chan, E.Y., Nasir, J., Gutekunst, C.A., Coleman, S., Maclean, A., Maas, A., Metzler, M., Gertsenstein, M., Ross, C.A., Nagy, A., et al. (2002). Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Hum. Mol. Genet. 11, 945-959.
7. de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P., and Deglon, N. (2002). Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22, 3473-3483. (Pubitemid 37465753)
8. de Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., Fukuhara, C., Battenberg, E.L., Gautvik, V.T., Bartlett, F.S., 2nd., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95, 322-327.
9. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993. (Pubitemid 27449140)
10. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G., et al. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. USA 104, 17204-17209.
11. Douaud, G., Gaura, V., Ribeiro, M.J., Lethimonnier, F., Maroy, R., Verny, C., Krystkowiak, P., Damier, P., Bachoud-Levi, A.C., Hantraye, P., et al. (2006). Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 32, 1562-1575. (Pubitemid 44332291)
12. Dragatsis, I., Zeitlin, S., and Dietrich, P. (2004). Huntingtin- associated protein 1 (Hap1) mutant mice bypassing the early postnatal lethality are neuroanatomically normal and fertile but display growth retardation. Hum. Mol. Genet. 13, 3115-3125.
13. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P., et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 65, 276-285.
14. Funato, H., Tsai, A.L., Willie, J.T., Kisanuki, Y., Williams, S.C., Sakurai, T., and Yanagisawa, M. (2009). Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 9, 64-76.
15. Gabery, S., Murphy, K., Schultz, K., Loy, C.T., McCusker, E., Kirik, D., Halliday, G., and Petersen, A. (2010). Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol. 120, 777-788.
16. Gray, M., Shirasaki, D.I., Cepeda, C., Andre, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E., et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28, 6182-6195.
17. Hara, J., Beuckmann, C.T., Nambu, T., Willie, J.T., Chemelli, R.M., Sinton, C.M., Sugiyama, F., Yagami, K., Goto, K., Yanagisawa, M., et al. (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345-354. (Pubitemid 32530580)
18. HDCRG. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
19. Hetherington, A.W., and Ranson, S.W. (1942). The relation of various hypothalamic lesions to adiposity in the rat. J. Comp. Neurol. 76, 475-499.
20. Hult, S., Schultz, K., Soylu, R., and Petersen, A. (2010). Hypothalamic and Neuroendocrine Changes in Huntington's Disease. Curr. Drug Targets 11, 1237-1249.
21. Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.W., Saiki, S., Rose, C., Krishna, G., Davies, J.E., Ttofi, E., Underwood, B.R., et al. (2008). Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412, 191-209. (Pubitemid 351758226)
22. Kassubek, J., Juengling, F.D., Kioschies, T., Henkel, K., Karitzky, J., Kramer, B., Ecker, D., Andrich, J., Saft, C., Kraus, P., et al. (2004). Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry 75, 213-220.
23. Kleinridders, A., Konner, A.C., and Bruning, J.C. (2009). CNS-targets in control of energy and glucose homeostasis. Curr. Opin. Pharmacol. 9, 794-804.
24. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H., et al. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wt huntingtin dosage. Hum. Mol. Genet. 16, 1845-1861.
25. Lalic, N.M., Maric, J., Svetel, M., Jotic, A., Stefanova, E., Lalic, K., Dragasevic, N., Milicic, T., Lukic, L., and Kostic, V.S. (2008). Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch. Neurol. 65, 476-480.
26. Li, X.J., Li, S.H., Sharp, A.H., Nucifora, F.C., Jr., Schilling, G., Lanahan, A., Worley, P., Snyder, S.H., and Ross, C.A. (1995). A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378, 398-402.
27. Li, S.H., Yu, Z.X., Li, C.L., Nguyen, H.P., Zhou, Y.X., Deng, C., and Li, X.J. (2003). Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. J. Neurosci. 23, 6956-6964. (Pubitemid 36951224)
28. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506. (Pubitemid 26374323)
29. Marder, K., Zhao, H., Eberly, S., Tanner, C.M., Oakes, D., and Shoulson, I. (2009). Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology 73, 385-392.
30. Martin, B., Golden, E., Carlson, O.D., Pistell, P., Zhou, J., Kim, W., Frank, B.P., Thomas, S., Chadwick, W.A., Greig, N.H., et al. (2009). Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes 58, 318-328.
31. Masaki, T., Yoshimichi, G., Chiba, S., Yasuda, T., Noguchi, H., Kakuma, T., Sakata, T., and Yoshimatsu, H. (2003). Corticotropin-releasing hormone-mediated pathway of leptin to regulate feeding, adiposity, and uncoupling protein expression in mice. Endocrinology 144, 3547-3554. (Pubitemid 36904434)
32. Mochel, F., Charles, P., Seguin, F., Barritault, J., Coussieu, C., Perin, L., Le Bouc, Y., Gervais, C., Carcelain, G., Vassault, A., et al. (2007). Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2, e647. 10.1371/journal.pone. 0000647.
33. Petersen, A., Gil, J., Maat-Schieman, M.L., Bjorkqvist, M., Tanila, H., Araujo, I.M., Smith, R., Popovic, N., Wierup, N., Norlen, P., et al. (2005). Orexin loss in Huntington's disease. Hum. Mol. Genet. 14, 39-47.
34. Phan, J., Hickey, M.A., Zhang, P., Chesselet, M.F., and Reue, K. (2009). Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 18, 1006-1016.
35. Phillips, W., Shannon, K.M., and Barker, R.A. (2008). The current clinical management of Huntington's disease. Mov. Disord. 23, 1491-1504.
36. Politis, M., Pavese, N., Tai, Y.F., Tabrizi, S.J., Barker, R.A., and Piccini, P. (2008). Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 131, 2860-2869.
37. Pouladi, M.A., Xie, Y., Skotte, N.H., Ehrnhoefer, D.E., Graham, R.K., Kim, J.E., Bissada, N., Yang, X.W., Paganetti, P., Friedlander, R.M., et al. (2010). Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet. 19, 1528-1538.
38. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richarson, J.A., Kozlowski, G.P., Wilson, S., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 1 page following 696.
39. Sheng, G., Chang, G.Q., Lin, J.Y., Yu, Z.X., Fang, Z.H., Rong, J., Lipton, S.A., Li, S.H., Tong, G., Leibowitz, S.F., et al. (2006). Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat. Med. 12, 526-533.
40. Soneson, C., Fontes, M., Zhou, Y., Denisov, V., Paulsen, J.S., Kirik, D., and Petersen, A. (2010). Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 40, 531-543.
41. Trejo, A., Tarrats, R.M., Alonso, M.E., Boll, M.C., Ochoa, A., and Velasquez, L. (2004). Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20, 192-196. (Pubitemid 38220981)
42. Tsuneki, H., Murata, S., Anzawa, Y., Soeda, Y., Tokai, E., Wada, T., Kimura, I., Yanagisawa, M., Sakurai, T., and Sasaoka, T. (2008). Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 51, 657-667.
43. Unger, T.J., Calderon, G.A., Bradley, L.C., Sena-Esteves, M., and Rios, M. (2007). Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J. Neurosci. 27, 14265-14274.
44. van der Burg, J.M., Bacos, K., Wood, N.I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J.I., Smith, R., Deierborg, T., Kuhar, M.J., et al. (2008). Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 29, 41-51.
45. Van Raamsdonk, J.M., Gibson, W.T., Pearson, J., Murphy, Z., Lu, G., Leavitt, B.R., and Hayden, M.R. (2006). Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet. 15, 1513-1523.
46. West, M.J. (1999). Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22, 51-61.
47. Weydt, P., Pineda, V.V., Torrence, A.E., Libby, R.T., Satterfield, T.F., Lazarowski, E.R., Gilbert, M.L., Morton, G.J., Bammler, T.K., Strand, A.D., et al. (2006). Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362. (Pubitemid 44645069)
48. Yamanaka, T., Tosaki, A., Miyazaki, H., Kurosawa, M., Furukawa, Y., Yamada, M., and Nukina, N. (2010). Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction. Hum. Mol. Genet. 19, 2099-2112.
49. Yi, C.X., Serlie, M.J., Ackermans, M.T., Foppen, E., Buijs, R.M., Sauerwein, H.P., Fliers, E., and Kalsbeek, A. (2009). A major role for perifornical orexin neurons in the control of glucose metabolism in rats. Diabetes 58, 1998-2005.
50. Zhang, X., Zhang, G., Zhang, H., Karin, M., Bai, H., and Cai, D. (2008). Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135, 61-73.